Osimertinib (OSI), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) (50), has been found to upregulate MCT1 expression in colorectal cancer (CRC) cells (51). The gene discussed is EGFR; the disease is colorectal carcinoma.